Clinical Trials Logo

Refractory Non-Hodgkin Lymphoma clinical trials

View clinical trials related to Refractory Non-Hodgkin Lymphoma.

Filter by:

NCT ID: NCT06119685 Recruiting - Multiple Myeloma Clinical Trials

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Start date: October 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.

NCT ID: NCT06097455 Not yet recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

CARTD-BG-1
Start date: January 15, 2024
Phase: Early Phase 1
Study type: Interventional

ths study consist in testing a CAR T therapy (ARI0003 cells (antiCD19 and antiBCMA) in patients suffering relapsed NHL (that means that symptoms of NHL reappeared ) or refractory (that means that they did not respond to other treatments). This is a first in human study.

NCT ID: NCT06026319 Recruiting - Clinical trials for Mantle Cell Lymphoma

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Start date: October 26, 2023
Phase: Phase 1
Study type: Interventional

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: - CD79b-19 CAR T cells - Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

NCT ID: NCT05967416 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: December 2023
Phase: Phase 1
Study type: Interventional

The goal of this study is to test SIRPant-M, an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.

NCT ID: NCT05892718 Recruiting - Clinical trials for Advanced Solid Tumor

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPĪ±-CD47 Pathway, in Solid or Hematological Tumors

Start date: October 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

NCT ID: NCT05828589 Recruiting - Clinical trials for Refractory Chronic Lymphocytic Leukemia

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Start date: June 20, 2023
Phase: Phase 1
Study type: Interventional

This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study aims to determine the maximum tolerated dose (MTD), maximum adminstered dose (MAD), recommended Phase 2 dose (RP2D), and pharmacokinetic profile of the drug. Additionally, preliminary antitumor activity will be characterized. The study is divided into 2 main parts: Part 1 "Monotherapy Dose Finding" and Part 2 "Monotherapy Dose Expansion."

NCT ID: NCT05826535 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

Study of IMPT-314 in R/R Aggressive B-cell NHL

Start date: May 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Two cohorts of participants will be enrolled: 1) CAR T naïve and 2) CAR T experienced. Up to approximately 60 patients (15 per dose level per cohort) will be enrolled in dose finding Phase 1 part of the study, which will determine the recommended phase 2 dose. Phase 2 will enroll up to approximately 40 additional participants (20 per cohort) to evaluate further the safety and efficacy of IMPT-314. IMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days. Individual participants will remain in the active post-treatment period for approximately 2 years. Participants will continue in long-term follow-up for 15 years from treatment.

NCT ID: NCT05627245 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphomas that have returned (relapsed) or resisted treatment (refractory). Tazemetostat is in a class of medications called EZH2 inhibitors. The EZH2 gene provides instructions for making a type of enzyme called histone methyltransferase which is involved in gene expression and cell division. Blocking EZH2 may help keep cancer cells from growing. Belinostat is in a class of medications called histone deacetylase inhibitors. Histone deacetylases are enzymes needed for cell division. Belinostat may kill cancer cells by blocking histone deacetylase. It may also prevent the growth of new blood vessels that tumors need to grow and may help make cancer cells easier to kill with other anticancer drugs. There is some evidence in animals and in living human cells that combination therapy with tazemetostat and belinostat can shrink or stabilize cancer, but it is not known whether this will happen in people. This trial may help doctors learn more about treatment of patients with relapsed or refractory lymphoma.

NCT ID: NCT05621096 Recruiting - Follicular Lymphoma Clinical Trials

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Start date: March 21, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: - If it is realistic to give people radiation treatment before they receive a chimeric antigen receptor (CAR) T-cell treatment for their cancer - If it is safe to give people radiation treatment before they receive a CAR T-cell treatment for their cancer

NCT ID: NCT05420493 Recruiting - Clinical trials for Non Hodgkin Lymphoma

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Start date: September 6, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and efficacy of CAR-T infusion preparation in the treatment of CD19-positive relapsed/refractory non-Hodgkin lymphoma.